跳到正文
原文
Endpoints News 生物医药· Nicole DeFeudis·· 26 天前AI 评分32

#ESMO26: 辉瑞在肺癌晚期失败后寻求新出路,BioNTech与百时美施贵宝展现早期活性

#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity

AI 导读

辉瑞正试图在肺癌晚期治疗失利后寻找新方向,其针对早期线患者的事后分析显示潜在积极信号。与此同时,BioNTech和百时美施贵宝在早期研究中展现出活性。

正文

MADRID — Pfiz­er is mov­ing past its late-stage loss in non-small cell lung can­cer, point­ing to a post-hoc analy­sis of ear­li­er-line pa­tients who ap­pear to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news